Parathyroid hormone analogues in the therapy of osteoporosis.
Müller
Markus
M
Medizinische Universität Wien/AKH, Universitätsklinik für Klinische Pharmakologie, AKH-Wien, Vienna, Austria. markus.mueller@meduniwien.ac.at
Pietschmann
Peter
P
D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016103:Spinal Fractures / Q000517:prevention & control*; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D019379:Teriparatide